Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02671955 · ClinicalTrials.gov registry record · Phase 1
A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer
A Phase 1 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02671955 is a Phase 1 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 12 participants.
The verdict
NCT02671955, a Phase 1 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of JNJ-61610588 in participants with advanced cancer in order to determine a recommended Phase 2 dose (RP2D) for further evaluation in specific tumor types.
Interventions
- DRUG JNJ-61610588
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-01 |
| Est. Completion | 2017-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02671955
The ClinicalTrials.gov registry entry for NCT02671955 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JNJ-61610588 is the first listed.
NCT02671955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02671955 about?
NCT02671955 is a clinical study titled "A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer". The purpose of this study is to evaluate the safety and tolerability of JNJ-61610588 in participants with advanced cancer in order to determine a recommended Phase 2 dose (RP2D) for further evaluation in specific tumor types.
What is the current status of trial NCT02671955?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2016-01. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02671955?
The interventions under investigation include: JNJ-61610588 (DRUG).
Who is sponsoring clinical trial NCT02671955?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.